Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-019-01545-4
Abstract: Background The open-label, randomized, active-controlled KEYNOTE-045 study (NCT02256436) showed that second-line pembrolizumab significantly improved overall survival (OS) of patients with advanced/metastatic urothelial cancer (UC) that progressed after first-line platinum-containing chemotherapy, compared with standard chemotherapy (paclitaxel,… read more here.
Keywords: chemotherapy; keynote 045; urothelial cancer; japanese patients ... See more keywords
Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").
Sign Up to like & getrecommendations! Published in 2019 at "Translational andrology and urology"
DOI: 10.21037/tau.2019.09.19
Abstract: The publication in 2017 of the KEYNOTE 045 prospective randomized phase 3 trial comparing pembrolizumab anti PD1 antibody with conventional cytotoxic chemotherapy in treatment of recurrent urothelial cancer (1) marked a watershed for immune treatment… read more here.
Keywords: keynote 045; urothelial cancer; commentary year; year follow ... See more keywords